Federal Register of Legislation - Australian Government

Primary content

This instrument is a notification that the Minister's delegate has exercised discretion under subsections 99ACB(6A) and 99ACF(3AA) of the National Health Act 1953 for brands of pharmaceutical items with approved ex-manufacturer price not reduced on 1 August 2021.
Administered by: Health
Registered 31 Jul 2021

Commonwealth Coat of Arms of Australia

 

 

I, Nikolai Tsyganov, Acting Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health and Aged Care make this determination under subsections 99ACB(6A) and 99ACF(3AA) of the National Health Act 1953.

Dated        30 July 2021

 

 

 

 

 

 

 

 

 

NIKOLAI TSYGANOV

Acting Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

 

 

 

 

 

 

 

1              Name of Determination

                This instrument is the National Health (August 2021 First New Brand statutory price reduction) (Exercise of Ministerial discretion) Determination 2021.  

2              Commencement

                This instrument commences on 1 August 2021.

3              Definition

 

              Note: A number of expressions used in this instrument are defined in Part VII the Act,

 

In this instrument:

  

   Act means the National Health Act 1953.

4              Authority

 

This instrument is made under subsection 99ACB(6A) and subsection 99ACF(3AA) of the Act.

5              Brands of pharmaceutical items with approved ex-manufacturer price not reduced

 

                (1) I determine under subsection 99ACB(6A) of the Act that, for the purposes of subsection 99ACB(5), the approved ex-manufacturer price that comes into force on 1 August 2021 of the brand of pharmaceutical item specified in column 2 of item 1 in the table in Schedule 1 is to be worked out using a reduction of zero %.

 

 

(2) I determine under subsection 99ACF(3AA) of the Act that, for the purposes of subsection 99ACF(2AB), the approved ex-manufacturer price that comes into force on 1 August 2021 of the brand of pharmaceutical item specified in column 2 of  item 2 in the table in Schedule 1 is to be worked out using a reduction of zero %.

 


Schedule 1 Brands of pharmaceutical items with approved ex-manufacturer price not reduced

 

Column 1

Column 2

Item

Brand of Pharmaceutical Item

 

Drug

Form

Manner of administration

Brand

1

Aciclovir

Eye ointment 30 mg per g, 4.5 g

Application to the Eye

XOROX

2

Aciclovir

Eye ointment 30 mg per g, 4.5 g

Application to the Eye

ViruPOS